CAS 2342583-66-6

9-(1-Cyclopropylethyl)-N2-(2-(dimethylamino)ethyl)-N6-(3-(trifluoromethyl)benzyl)-9H-purine-2,6-diamine

CAS : 2342583-66-6

Formule : C₂₂H₂₈F₃N₇

Degré de pureté : 98%

Masse moléculaire : 447.4998

Ref: IN-DA01KKFG

NCC007

CAS : 2342583-66-6

NCC007

Degré de pureté : ≥98%

Masse moléculaire : 447.5g/mol

Ref: 54-BUP10430

NCC007

CAS : 2342583-66-6

NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.

Formule : C₂₂H₂₈F₃N₇

Degré de pureté : 98.88%

Couleur et forme : Solid

Masse moléculaire : 447.5

Ref: TM-T7949

NCC007

CAS : 2342583-66-6

NCC007 is a drug that inhibits casein kinase. Casein kinase is involved in cell proliferation and differentiation. NCC007 is being studied for its potential use as an anticancer therapeutic. Inhibition of casein kinase leads to the phosphorylation of casein, which may inhibit tumor growth by disrupting the circadian rhythm. NCC007 has been shown to be effective against cancer cells grown in vitro and in vivo. This drug also has the ability to modulate cellular pathways, such as endogenous protein synthesis, cellular signaling, and cell cycle progression. Optimization of cancer drugs has been shown using x-ray crystal structures of the human protein Csk-1 (casein kinase).

Formule : C₂₂H₂₈F₃N₇

Degré de pureté : Min. 95%

Masse moléculaire : 447.5 g/mol

Ref: 3D-STD58366